FATAL OUTCOMES FROM DRUG INTERACTIONS: INSIGHTS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM

被引：0
|
作者：
Gomez-Lumbreras, A. [1 ]
Villa, Zapata L. [2 ]
Malone, D. [1 ]
机构：
[1] Univ Utah, Dept Pharmacotherapy, Coll Pharm, Salt Lake City, UT USA
[2] Univ Georgia, Coll Pharm, Atlanta, GA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH103
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [31] Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
    Sonawane, Kalyani B.
    Cheng, Ning
    Hansen, Richard A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 682 - 690
  • [32] Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
    Cecco, Sara
    Puligheddu, Stefano
    Fusaroli, Michele
    Gerratana, Lorenzo
    Yan, Miao
    Zamagni, Claudio
    De Ponti, Fabrizio
    Raschi, Emanuel
    [J]. TARGETED ONCOLOGY, 2024, 19 (03) : 435 - 445
  • [33] Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
    Barbieri, Maria Antonietta
    Russo, Giulia
    Sorbara, Emanuela Elisa
    Cicala, Giuseppe
    Franchina, Tindara
    Santarpia, Mariacarmela
    Speranza, Desiree
    Spina, Edoardo
    Silvestris, Nicola
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
    Wang, Qi
    Liu, Jingfang
    Sun, Hao
    Dong, Yongfei
    Tan, Weiliang
    Tang, Zaixiang
    Jiang, Yiguo
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 107 - 117
  • [35] Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
    Bai, Yang
    Wu, Bin
    Gou, Liangwen
    Fang, Zhenwei
    Xu, Ting
    Zhang, Tiejun
    Li, Yuwen
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [36] Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
    Wichelmann, Thomas A.
    Abdulmujeeb, Sufyan
    Ehrenpreis, Eli D.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1290 - 1297
  • [37] Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS)
    He, Sidi
    Chen, Bin
    Li, Chuanwei
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):
  • [38] Performance of subgrouped proportional reporting ratios in the US food and drug administration (FDA) adverse event reporting system
    Dauner, Dan
    Zhang, Rui
    Adam, Terrence
    Leal, Eleazar
    Farley, Joel F.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 598 - 598
  • [39] Performance of subgrouped proportional reporting ratios in the US Food and Drug Administration (FDA) adverse event reporting system
    Dauner, Daniel G.
    Zhang, Rui
    Adam, Terrence J.
    Leal, Eleazar
    Heitlage, Viviene
    Farley, Joel F.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (07) : 589 - 597
  • [40] Identification of Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha S.
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 406 - 407
12345